DECEMBER 5-9, 2023

HENRY B. GONZALEZ CONVENTION CENTER

SAN ANTONIO, TEXAS

SABCS-2023-cluster-logo-reverse
Preliminary Program

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow.
In person and virtual attendance is available.


Tuesday, December 5, 2023 All times are CENTRAL Time


12:00 pm - 2:00 pm

CONCURRENT SPECIAL SESSIONS


Special Session 1 Industry and the Regulatory Bodies- New Designs and Approval, Hemisfair Ballroom 1-2

Details to be announced

Special Session 2 Prevention, Early Detection, and Interception, Stars at Night Ballroom 3-4
Moderator: Carol J. Fabian, University of Kansas Medical Center, Kansas City, Missouri

What is polygeneic risk score & how is it used?
Suzette Delaloge, Gustave Roussy, Villejuif, France

Hormone replacements and alternative for women at population and moderately increased risk
Carol J. Fabian, University of Kansas Medical Center, Kansas City, Kansas

HRT after BSO +/- hysterectomy in premenopausal BRCA1/2 mutation carriers
Joanne Kotsopoulos, Women's College Research Institute, Toronto, Ontario, Canada

Speaker to be announced

Special Session 3 Social Determinants of Health: Impact on Cancer Care, Stars at Night Ballroom 2
Moderator: Amelie G. Ramirez, UT Health Science Center at San Antonio, San Antonio, Texas

What are social determinants of health and why are they important to cancer care?
Amelie G. Ramirez, UT Health Science Center San Antonio, San Antonio, Texas

Multilevel barriers to addressing social risks: Data from select NCI cancer settings

Brenda Adjei, National Cancer Institute, Bethesda, Maryland


How do hospitals/clinics utilize SDoH data?

Brian M. Rivers, Morehouse School of Medicine Cancer Health Equity Institute, Atlanta, Georgia


Once social determinants of health are determined, what processes need to be in place to reduce the burden on patients?
Sandi L. Pruitt, UT Southwestern Medical Center, Dallas, Texas

How is the impact of SDoH being evaluated at clinical/hospital and community levels?
Susan T. Vadaparampil, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Advocate Response
Barbara Segarra, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico

Additional Speakers to be announced

Panel Discussion



2:00 pm - 3:00 pm

CONCURRENT WORKSHOPS


Clinical Workshop: Tumor Agnostic Approaches to Care, Stars at Night Ballroom 2

Moderator: Sangeetha M. Reddy, UT Southwestern Medical Center, Dallas, Texas

Agnostic trials in the field of targeted therapies
Vivek Subbiah, UT MD Anderson Cancer Center, Houston, Texas

ADC development across tumor types
Joshua Z. Drago, Memorial Sloan Kettering Cancer Center, New York, New York

Real World Data
Mia A. Levy, Foundation Medicine, Inc., Cambridge, Massachusetts

Defining a biologic entity that is sensitive to immunotherapeutic
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands



Materials and Methods: Basic Science to Breast Oncology Workshop, Stars at Night Ballroom 3-4
Moderator: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

Organoids
Calvin J. Kuo, Stanford University, Stanford, California

Single cell sequencing
Elham Azizi, Columbia University, New York, New York

Real-World Genomics
Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Speaker to be announced
3:00 pm - 3:15 pm BREAK
3:15 pm - 5:15 pm CONCURRENT EDUCATIONAL SESSION BLOCK #1

ED01: Latest Trends in Adjuvant Endocrine Therapy, Stars at Night Ballroom 3-4
Moderator: Fabrice André, Gustave Roussy, Villejuif, France

Optimizing endocrine therapy in premenopausal women
Vered Stearns, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

How to treat postmenopausal patients
Rachel Freedman, Dana-Farber Cancer Institute, Boston, Massachusetts

Who benefits from CDK 4/6 inhibitors and chemotherapy in the adjuvant setting?
Otto Metzger, Dana-Farber Cancer Institute, Boston, Massachusetts

ED02: Lobular Breast Cancer, Stars at Night Ballroom 1-2
Moderator: Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Biological peculiarities of ILC
Christine Desmedt, KU Leuven, Leuven, Belgium

Diagnosis, prognosis, and surveillance: What is different?
Tari A. King, Dana-Farber Cancer Institute, Boston, Massachusetts

Innovative approaches for lobular breast cancer
Jason Aboudi Mouabbi, UT MD Anderson Cancer Center, Houston, Texas

Panelist: Siobhán Freeney, European Lobular Breast Cancer Foundation, Dublin, Ireland

ED03: Overcoming Obesity-Associated Breast Cancer Risk, Hemisfair Ballroom 1-2
Moderator: Abenaa M. Brewster, UT MD Anderson Cancer Center, Houston, Texas

How much weight loss is needed to break the obesity-cancer link?
Stephen D. Hursting, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Interventions: Medical and lifestyle
Randy Seeley, University of Michigan, Ann Arbor, Michigan

Impact of exercise on breast cancer outcomes
Kerry S. Courneya, University of Alberta, Edmonton, Alberta, Canada
Panelist: Joanne Taylor, Abcdiagnosis, London, England

ED04: Treatment Post-CDK 4/6 Inhibitors, Hemisfair Ballroom 3
Moderator: Stephanie Graff, Lifespan Cancer Institute, Providence, Rhode Island

Single agent endocrine therapy
Carlos H. Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

Combination endocrine therapy
Ruth O’Regan, University of Rochester, Rochester, New York

When to transition to cytotoxics
Erica Stringer-Reasor, University of Alabama at Birmingham, Birmingham, Alabama

Panelist: Abigail Johnston, Surviving Breast Cancer, Orlando, Florida
5:15 pm - 5:30 pm BREAK
5:30 pm - 6:30 pm

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #1


Wednesday, December 6

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #2 

8:00 am - 8:15 am  BREAK
8:15 am - 8:30 am

Welcome and Opening Remarks, Hall 4

8:30 am - 9:00 am 

William L. McGuire Memorial Lecture, Hall 4

9:00 am - 12:00 pm  GENERAL SESSION 1, Hall 4
12:00 pm  EXHIBITS OPEN, Halls 1-2
12:00 pm - 2:00 pm 

POSTER SESSION 1, Halls 1-2

1:00 pm - 2:00 pm    CONCURRENT SESSIONS

Debate: Anthracyclines…To give or not to give? Stars at Night Ballroom 1-2
Moderator: Harold J. Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts

“For”
Martine J. Piccart, Institut Jules Bordet, Brussels, Belgium


“Against”
Virginia F. Borgers, University of Colorado Anshutz Medical Campus, Aurora, Colorado


State-of-the-Art Session 1: Immunotherapy: Purpose, Resistance, and Toxicity, Stars at Night Ballroom 1-2
Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Biomarkers predicting immune related adverse events
Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, Massachusetts

Cellular therapies: What is the outlook for breast and other solid cancers?
Valentina Hoyos Velez, Baylor College of Medicine, Houston, Texas

Tumor mechanisms of resistance to immunotherapy
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Chromosomal instability & resistance to immunotherapy
Kevin Litchfield, University College London, London, England

2:00 pm - 3:00 pm 

Molecular Tumor Board, Hemisfair Ballroom 1-2

Moderator: Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York

Panelists:

Giuseppe Curigliano, European Institute of Oncology, Milan, Italy

Gaorav Gupta, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Celina G. Kleer, University of Michigan, Ann Arbor, Michigan

Nancy U. Lin, Dana-Farber Cancer Institute, Boston, Massachusetts

Elizabeth A. Morris UC Davis School of Medicine, Sacramento, California

Joyce A. O'shaughnessy, Baylor University Medical Center, Dallas, Texas


3:00 pm - 5:00 pm

CONCURRENT EDUCATIONAL SESSION BLOCK #2


ED05: Controversies in Local Regional Management, Hemisfair Ballroom 1-2
Moderator: Debra Patt, Texas Oncology, Austin, Texas

Demystifying the axilla: Challenging scenarios in the upfront surgery setting and after neoadjuvant chemotherapy
Andrea V. Barrio, Memorial Sloan Kettering Cancer Center, New York, New York

When less is more: Patient-friendly radiation courses with WBI and PBI
Icro Meattini, Università degli Studi di Firenze, Florence, Italy

Surgical management of clinical stage I HER 2+ and triple negative breast cancer
Anita Mamtani, Memorial Sloan Kettering Cancer Center, New York, New York
Speaker to be announced
Panelist: Jamie LaScala, Translational Center of Excellence in Breast Cancer, Penn Medicine, Philadelphia, Pennsylvania

ED06: Coordinated Care of Brain Metastasis, Hemisfair Ballroom 3
Moderator: Carey K. Anders, Duke University Comprehensive Cancer Center, Durham, North Carolina
Speakers:
Rebecca Dent, National Cancer Centre Singapore, Singapore
Christopher D. Lascola, Duke University Medical Center, Durham, North Carolina
Nelson Moss, Memorial Sloan Kettering Cancer Center, New York, New York
Helen A. Shih, Massachusetts General Hospital, Boston, Massachusetts
Jeffrey Wefel, UT MD Anderson Cancer Center, Houston, Texas

ED07: HER2+ Breast Cancer: Updates from the Clinic and the Lab, Stars at Night Ballroom 1-2
Moderator: Mothaffar F. Rimawi, Baylor College of Medicine, Houston, Texas

Molecular determinates of response and resistance in HER2+ breast cancer
Ron Bose, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Recent advances in systemic disease
Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

Management of brain metastases
Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, Massachusetts
Panelist: Terlisa Sheppard, Terlisa Fights Breast Cancer, Inc., Florida

ED08: Toxicity Management: Next-Gen Therapies Means Next-Gen Toxicities, Stars at Night Ballroom 3-4
Moderator: Antonio C. Wolff, Johns Hopkins University, Baltimore, Maryland

Antibody drug conjugates
Heather L. McArthur, UT Southwestern Medical Center, Dallas, Texas

Targeted therapeutics in hormone positive breast cancers
Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts

Immunotherapies – short and long term
Douglas B. Johnson, Vanderbilt University Medical Center, Nashville, Tennessee

Panelist: Sheila Johnson, Komen Advocates in Science, Swansea, Illinois
5:00 pm - 7:00 pm    

POSTER SESSION 2, Halls 1-2

5:30 pm - 6:30 pm 

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #3

7:00 pm 

EXHIBITS CLOSE, Halls 1-2


Thursday, December 7

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #4 

8:00 am - 8:15 am  BREAK
8:15 am - 11:15 am

General Session 2, Hall 4

11:15 am - 11:45 am 

Plenary Lecture 1, Hall 4

Tumor heterogeneity and evolution in breast cancer
Charles Swanton, The Francis Crick Institute, London, England

1145 am - 12:00 pm  BREAK
12:00 pm  EXHIBITS OPEN, Halls 1-2
12:00 pm - 2:00 pm 

POSTER SESSION 3, Halls 1-2

1:00 pm - 1:30 pm AACR Distinguished Lectureship in Breast Cancer Research, supported by Aflac Inc., Stars at Night Ballroom 1-2
1:00 pm - 2:00 pm    CONCURRENT SESSIONS

Clinical Case Discussions, Stars at Night Ballroom 3-4
Moderator: Matthew P. Goetz, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Panelists:
Fabrice André, Gustave Roussy, Villejuif, France
Nadia Harbeck, LMU University Hospital, Munich, Germany
Erica L. Mayer, Dana-Farber Cancer Institute, Boston, Massachusetts
Aleix Prat, Hospital Clínic Barcelona, Barcelona, Spain
Hope S. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California


State-of-the-Art Session 2: Implications of Senescence for Breast Cancer Biology and Treatment, Hemisfair Ballroom 1-2
Moderator: Justin M. Balko, Vanderbilt University, Nashville, Tennessee

Speaker to be announced

Implications of therapy induced senescence in breast cancer
James G. Jackson, Tulane University School of Medicine, New Orleans, Louisiana

Clinical trials and new therapeutics
Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia

2:00 pm - 3:00 pm 

Clinical Controversies, Stars at Night Ballroom 3-4

Moderator: Lisa A. Carey, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

Are we ready to stop staging the axilla?
Monica Morrow, Memorial Sloan Kettering Cancer Center, New York, New York
Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, California

How to treat small triple negative breast cancer
Priyanka Sharma, University of Kansas Medical Center, Kansas City, Kansas
Alexandra Thomas, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Biology or stage? Tailoring treatment for premenopausal women with nodal involvement, but low oncotype
Eric P. Winer, Yale Cancer Center, New Haven, Connecticut
Kevin M. Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia

3:00 pm - 5:00 pm

CONCURRENT EDUCATIONAL SESSION BLOCK #3


ED09: Genomics for the Clinician, Stars at Night Ballroom 3-4
Moderator: Norah Lynn Henry, Rogel Cancer Center University of Michigan, Ann Arbor, Michigan

Speaker to be announced
Tumor tissue vs. ctDNA
Ben O'Leary, Royal Marsden Hospital, London, England

When do you order and how to interpret genomic testing
Jorge S. Reis-Filho, Memorial Sloan Kettering Cancer Center, New York, New York

ED10: PI(3)king the Right Target, Stars at Night Ballroom 3-4
Moderator: Cynthia X. Ma, Washington University Siteman Cancer Center, Saint Louis, Missouri

PI3 Kinase
Neil Vasan, Columbia University Irving Medical Center, New York, New York

AKT pathway
Alex Toker, Beth Israel Deaconess Medical Center, Boston, Massachusetts

mTOR pathway
Robert J. Schneider, NYU Grossman School of Medicine, New York, New York

ED11: Inflammatory Breast Cancer: Clinical Challenges, Evolving Concepts and Novel treatments (People’s Choice), Hemisfair Ballroom 1-2
Moderator and Speakers to be announced
5:00 pm - 7:00 pm    

POSTER SESSION 4, Halls 1-2

5:30 pm - 6:30 pm 

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #5

7:00 pm 

EXHIBITS CLOSE, Halls 1-2


Friday, December 8

7:00 am - 8:00 am

CONCURRENT POSTER SPOTLIGHT SESSIONS BLOCK #6

8:00 am - 8:15 am  BREAK
8:15 am - 11:15 am

General Session 3, Hall 4

11:15 am - 11:45 am 

Plenary Lecture 2, Hall 4

Recent advances in triple negative breast cancer
Melinda L. Telli, Stanford University School of Medicine, Stanford, California
11:45 am - 12:00 pm  BREAK
12:00 pm  EXHIBITS OPEN, Halls 1-2
12:00 pm - 2:00 pm 

POSTER SESSION 5, Halls 1-2

1:00 pm - 1:30 pm

AACR Outstanding Investigator Award for Breast Cancer Research, supported by the Breast Cancer Research Foundation, Stars at Night Ballroom 1-2

1:30 pm - 2:30 pm    CONCURRENT SESSIONS

Translational Research Controversies, Stars at Night Ballroom 3-4
Moderator: Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, New York

Baby-TAM
Per Hall, Karolinska Institutet, Stockholm, Sweden
Jack Cuzick, Queen Mary University of London, London, England

When to do a window trial
Mitchell Dowsett, Royal Marsden Hospital, London, England
Sara A. Hurvitz, UCLA – University of California Los Angeles, Los Angeles, California

Are we sequencing too late?
Charles M. Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Fabrice André, Gustave Roussy, Villejuif, France


State-of-the-Art Session 3: Targeting Mutant ER, Hemisfair Ballroom 1-2
Moderator: Aditya Bardia, Massachusetts General Hospital, Boston, Massachusetts

Biological consequences of ESR1 mutation
Geoffrey L. Greene, University of Chicago, Chicago, Illinois

Tracking mutant ER using ctDNA
François-Clément Bidard, Institut Curie, Paris, France

The future of oral SERDs
Erika P. Hamilton, Sarah Cannon Research Institute, Nashville, Tennessee


2:30 pm - 2:45 pm 

BREAK

2:45 pm - 3:45 pm
Year in Review, Hall 4
Moderator: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas

Advanced Breast Cancer
Mariana Chavez-Mac Gregor, UT MD Anderson, Houston, Texas

Early Breast Cancer
Ann H. Partridge, Dana-Farber Cancer Institute, Boston, Massachusetts

Basic Science

Heide L. Ford, University of Colorado Denver School of Medicine, Denver, Colorado


Translational
Jennifer K. Richer, University of Colorado Anshutz Medical Campus, Aurora, Colorado

3:45 pm - 4:00 pm    

BREAK

4:00 pm

Exhibits Close, Hall 1-2

4:00 pm - 6:00 pm 
View from the Trenches: What will You do on Monday Morning? Hall 4
Moderator: Sara M. Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts

Panelists:
Javier Cortes Castan, Ramón y Cajal University Hospital, Madrid, Spain
Lesley Glenn, Project Life, Central Point, Oregon
Sara A. Hurvitz, University of California Los Angeles, Los Angeles, California
Joyce A. O'Shaughnessy, Baylor University Medical Center, Dallas, Texas
Richard C. Zellars, Indiana University School of Medicine, Indianapolis, Indiana

Saturday, December 9

7:00 am - 11:00 am

Career Development Day

Details to be announced